Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy

NCT03630991 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03630991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03630991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
October 11, 2018
Completion date
April 30, 2027
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, acute myeloid leukemia arising from previous myelodysplastic syndrome, blast phase chronic myelogenous leukemia, bcr-abl1 positive, chronic myelogenous leukemia, bcr-abl1 positive, high risk myelodysplastic syndrome, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, myeloproliferative neoplasm, recurrent acute myeloid leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent myelodysplastic syndrome, recurrent myelodysplastic/myeloproliferative neoplasm, refractory acute myeloid leukemia, refractory chronic myelogenous leukemia, bcr-abl1 positive, refractory myelodysplastic syndrome, secondary acute myeloid leukemia, secondary myelodysplastic syndrome, very high risk myelodysplastic syndrome